Biogen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

23.04.18	New SPINRAZA® (nusinersen) Data Unveiled at AAN Annual Meeting Show Continued Improvement in Motor Function for Broad Age Range and Survival Benefit for Infants (Businesswire)
23.04.18	BHVN In Focus, Fresenius Calls Off Deal To Buy AKRX, Good News For GUD (RTTNews)
20.04.18	Biogen, Ionis Expand Collaboration; Biogen To Pay $1 Bln To License Therapies (RTTNews)
20.04.18	Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases (Businesswire)
17.04.18	Biogen Builds on Its 40-Year Legacy in Neuroscience with Presentation of Research from Its Portfolio of Medicines and Investigational Programs for Neurodegenerative Diseases (Businesswire)
05.04.18	Biogen, Samsung Bioepis Announce Deal With Abbvie For Imraldi Commercialization (RTTNews)
05.04.18	Biogen and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercialization of IMRALDI™ (Adalimumab Biosimilar) in Europe (Businesswire)
28.03.18	Biogen to Report First Quarter 2018 Financial Results on April 24, 2018 (Businesswire)
15.03.18	Biogen to Present at the 2018 Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting (Businesswire)
15.03.18	Biogen to Present at the Advances in Alzheimer’s and Parkinson’s Therapies, an AAT-AD/PD Focus Meeting (Businesswire)
12.03.18	Biogen Announces New Interim Phase 2 Results From NURTURE (RTTNews)
12.03.18	Biogen To Acquire Phase 2b Ready Asset For Schizophrenia (RTTNews)
12.03.18	Biogen to Acquire from Pfizer First-in-Class Phase 2b Ready Asset for Cognitive Impairment Associated with Schizophrenia (Businesswire)
12.03.18	New Data Presented at MDA Clinical Conference Show Benefit in Motor Function for Infants, Teens and Young Adults Treated With SPINRAZA® (nusinersen) (Businesswire)
07.03.18	Zinbrynta Now Connected To Brain Inflammation (RTTNews)
02.03.18	Biogen, AbbVie Voluntarily Withdraw Worldwide MA For ZINBRYTA - Quick Facts (RTTNews)
02.03.18	Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis (Businesswire)
28.02.18	Biogen to Present at the Cowen and Company 38th Annual Health Care Conference (Businesswire)
14.02.18	The New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy (Businesswire)
07.02.18	Biogen: Primary And Secondary Endpoints Not Met In Natalizumab Phase 2b Study (RTTNews)
07.02.18	Biogen Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Ischemic Stroke (Businesswire)
25.01.18	Biogen To Acquire Karyopharm's Investigational Oral SINE Compound KPT-350 (RTTNews)
25.01.18	Biogen Inc. Bottom Line Advances In Q4 (RTTNews)
22.01.18	Sanofi In Deal To Buy Hemophilia Drugmaker Bioverativ For $11.6 Bln; Stock Dips (RTTNews)
22.01.18	WSJ : Sanofi Nears Deal To Buy Bioverativ For More Than $11.5 Bln (RTTNews)
04.01.18	Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018- Updated Call Timing (Businesswire)
21.12.17	Adaptive Phase II Study of BAN2401 in Early Alzheimer’s Disease Continues toward 18-Month Endpoint (Businesswire)
20.12.17	Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018 (Businesswire)
20.12.17	EXEL, PFE, ONCE Get FDA Nod, FPRX, ZLAB Team Up, SKLN Soars After Hours (RTTNews)
19.12.17	Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy (Businesswire)
18.12.17	Biogen to Present at the 36th Annual J.P. Morgan Healthcare Conference (Businesswire)
07.12.17	Biogen to Present at the Guggenheim 5th Annual Healthcare Conference (Businesswire)
04.12.17	Biogen Appoints Mark Hernon as SVP, Chief Information Officer (Businesswire)
28.11.17	BIIB & ALKS Team Up For MS Drug, REGN's Eylea Combo Fails Again, AEZS Rises (RTTNews)
27.11.17	Biogen In Deal With Alkermes To Develop, Commercialize ALKS 8700 For MS (RTTNews)
27.11.17	Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis (Businesswire)
21.11.17	Biogen Names Jeff Capello CFO (RTTNews)
21.11.17	Biogen Appoints Jeff Capello as Executive Vice President and Chief Financial Officer (Businesswire)
20.11.17	Biogen to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference (Businesswire)
02.11.17	Biogen Appoints Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation (Businesswire)
02.11.17	Biogen Presents New Data from Long-Term Extension of Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab (Businesswire)
01.11.17	The New England Journal of Medicine Publishes First Phase 3 Study Results of SPINRAZA® for the Treatment of Spinal Muscular Atrophy (Businesswire)
30.10.17	Biogen to Present at the Clinical Trials on Alzheimer’s Disease Conference (Businesswire)
27.10.17	Biogen and Ionis Win Prestigious Prix Galien Award for SPINRAZA as Best Biotechnology Product (Businesswire)
25.10.17	Biogen Initiates AFFINITY Phase 2 Trial For Opicinumab In Multiple Sclerosis (RTTNews)
25.10.17	Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis (Businesswire)
24.10.17	Biogen Amends Deal With Neurimmune On Aducanumab; Boosts Profit Potential (RTTNews)
24.10.17	Biogen Inc. Q3 Earnings Rise 25% (RTTNews)
23.10.17	Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease Treatments Including Phase 3 Aducanumab (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Geberit	512.60	3.62 %	K V
Logitech Intl	80.88	2.15 %	K V
UBS Group	29.96	1.97 %	K V
Sika	222.20	1.55 %	K V
Sonova Hldg	304.70	1.43 %	K V
Roche Hldg G	264.60	0.46 %	K V
Novartis	90.51	0.44 %	K V
Alcon	75.92	0.29 %	K V
CieFinRichemont	139.85	-0.25 %	K V
Nestle	73.60	-0.76 %	K V

mehr

15:58		Zuversicht in Europa: Euro STOXX 50 präsentiert sich nachmittags fester
15:58		Starker Wochentag in Frankfurt: LUS-DAX nachmittags mit Gewinnen
15:58		Zuversicht in Frankfurt: DAX steigt am Mittwochnachmittag
15:52		Investment-Tipp Sartorius vz-Aktie: Bernstein Research bewertet Anteilsschein in neuer Analyse
12:50		Bayer-Aktie aber freundlich: Bayer kassiert nächste PCB-Niederlage in USA - Warten auf höchstes Staatsgericht
12:26		Freundlicher Handel in Europa: Anleger lassen Euro STOXX 50 mittags steigen
12:26		Handel in Frankfurt: LUS-DAX mittags mit grünem Vorzeichen
12:26		Freundlicher Handel: TecDAX bewegt sich mittags im Plus

15:58

Zuversicht in Europa: Euro STOXX 50 präsentiert sich nachmittags fester

15:58

Starker Wochentag in Frankfurt: LUS-DAX nachmittags mit Gewinnen

15:58

Zuversicht in Frankfurt: DAX steigt am Mittwochnachmittag

15:52

Investment-Tipp Sartorius vz-Aktie: Bernstein Research bewertet Anteilsschein in neuer Analyse

12:50

Bayer-Aktie aber freundlich: Bayer kassiert nächste PCB-Niederlage in USA - Warten auf höchstes Staatsgericht

12:26

Freundlicher Handel in Europa: Anleger lassen Euro STOXX 50 mittags steigen